Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | PARP1 | P09874 | 5/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555992 | 0.85 | PARP1 (0.54) | LMNAPARP1ARFLT1KDR | |
| SCHEMBL4698381 | 0.84 | ENPP1 (0.50) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL4697340 | 0.83 | LMNA (0.73) | LMNAPARP1ARHTTNPSR1 | |
| SCHEMBL4697620 | 0.83 | PARP1 (0.50) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL4702788 | 0.83 | CYP3A4 (0.53) | LMNAPARP1ARKMT2AMEN1 | |
| SCHEMBL4700133 | 0.82 | PARP1 (0.49) | LMNAPARP1ARKMT2AMEN1 | |
| SCHEMBL1789242 | 0.81 | LMNA (1.00) | LMNAPARP1ARHTTNPSR1 | |
| SCHEMBL29349943 | 0.81 | LMNA (1.00) | LMNAPARP1ARHTTNPSR1 | |
| SCHEMBL4702972 | 0.79 | ENPP1 (0.49) | LMNAPARP1ARSMN1; SMN2ENPP1 | |
| SCHEMBL4698988 | 0.79 | PARP1 (0.48) | LMNAPARP1ARENPP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | claimed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | claimed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | claimed |
| EP-1427708-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-16 | — | — | EP | claimed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | claimed |
| WO-2003014090-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | disclosed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| EP-1427708-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-16 | — | — | EP | disclosed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | disclosed |
| WO-2003014090-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K15, MAP3K5 | LMNA 2771/4885PARP1 1385/4885AR 1887/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | LMNA 2414/4885PARP1 1467/4885AR 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.